November 18, 2013
Pharmacosmos to join the 9th Congress of ECCO
Inflammatory Bowel Diseases 2014 in Copenhagen.
Pharmacosmos will join the 9th Congress of ECCO Inflammatory
Bowel Diseases 2014, to be held in Copenhagen February 20-22,
Pharmacosmos will participate with a booth and will also be
hosting a satellite symposium entitled "Optimising iron treatment
for IBD patients - NEW clinical data and a NEW e-tool," on Thursday
20th. February at 11:30 am.
ECCO is the European Crohn's and Colitis Organisation and
the congress is the major European educational event in the field
of Inflammatory Bowel Diseases (IBD) and has achieved large
popularity across the world.
ECCO 2014 in Copenhagen will provide a unique opportunity
to gain access to the latest and best scientific information and
education in adult and paediatric gastroenterology, hepatobiliary
disease, endoscopy, imaging, gastrointestinal surgery related to
The congress aims are to advance the understanding of
digestive disorders, to improve the development of guidelines
through the most robust process, to define better and valid
outcomes for the therapy of IBD, all to enhance patient care. By
promoting research, integrating basic science and clinical
practice, fostering international collaboration and friendship, IBD
experts strive to bring hope and comfort to the many people who
suffer from IBD.
Please visit www.ecco-ibd.eu/ecco14
for further information.
About Pharmacosmos A/S
Pharmacosmos develops and markets
medicines for the treatment of iron deficiency. A research-based
company, its ongoing R&D programme focuses on improving the
treatment options for healthcare professionals, patients suffering
from iron deficiency and veterinary treatments. .
Pharmacosmos is a family-owned
Danish company and operates in more than 60 countries across
Europe, the Americas and Asia. Its facilities are approved by both
the Danish Medicines Agency and the US Food & Drug